Is Alto Neuroscience, Inc. (ANRO) a Buy, Sell, or Hold?
Alto Neuroscience, Inc.
NYSE:ANRO
$27.8 USD
-$0.23 (-0.82%)
- Volume
- 559.92K
- Average Volume
- 461.2K
- Market Capitalization
- $975.61M
- P/E Ratio
- -11.21
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $28.85
- Year Low
- $2.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.52
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Amit Etkin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ANRO |
| CUSIP | 02157Q109 |
| CIK | 0001999480 |
| Web | https://www.altoneuroscience.com |
| Phone | (650) 200-0412 |
| Currency | USD |
| Employees | 68 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 20.52 |
| Quick Ratio | 20.52 |
| Cash Ratio | 20.11 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.91 |
| Price / Cash Flow | -15.52 |
| Price / Book | 3.76 |
Price Target and Rating
| Average Stock Price Forecast | $35.00 |
| High Stock Price Forecast | $50.00 |
| Low Stock Price Forecast | $24.00 |
| Forecast Upside/Downside | -20.57% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.19 |
| Trailing P/E Ratio | -11.21 |
| PEG Ratio | 1.52 |
| P/E Growth | 1.52 |
| Net Income | $-63.24M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -47.22% |
| Return on Assets | -26.90% |
Financials Score
| AltmanZ Score | 16.05 |
| Piotroski Score | 2.00 |
| Working Capital | 256.01M |
| Total Assets | 276.26M |
| Ebit | -71.89M |
| Market Cap | 929.29M |
| Total Liabilities | 32.89M |
Poll Results
About Alto Neuroscience, Inc. (NYSE:ANRO) Stock
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor invers ... e agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
2026-07-13 07:47:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected.
2026-06-15 08:03:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major d.
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
2026-05-28 09:00:00
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuro
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
2026-05-28 08:03:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuros.
2026-05-15 08:27:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributio.
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 07:03:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b trial of ALTO-207 in T.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-05-11 16:05:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: Bank of America Securities Healthcare Conference, May 12-14, 2026 Format: Company presentation and one-on-one meetings Presentation Date & Time: May 1.
2026-05-04 08:03:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry (SOBP). ALTO-20.
Frequently Asked Questions
-
What is the current Alto Neuroscience, Inc. (ANRO) stock price?
-
Alto Neuroscience, Inc.(NYSE:ANRO) stock price is $27.8 in the last trading session. During the trading session, ANRO stock reached the peak price of $28.85 while $2.53 was the lowest point it dropped to. The percentage change in ANRO stock occurred in the recent session was --0.82% while the dollar amount for the price change in ANRO stock was -$-0.23.
-
ANRO's industry and sector of operation?
-
The NYSE listed ANRO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ANRO?
-
Erin R. McQuade | General Counsel, Chief Administrative Officer & Corporate Secretary
Amit Etkin | Founder, Chairman of the Board, Chief Executive Officer & President
Nicholas C. Smith | Chief Financial Officer & Chief Business Officer
Adam Savitz | Chief Medical Officer
Dan Segal | Co-Founder & Strategic Advisor -
How many employees does ANRO have?
-
Number of ANRO employees currently stands at 68. ANRO operates from 369 South San Antonio Road, Mountain View, CA 94022, US.
-
Link for ANRO official website?
-
Official Website of ANRO is: https://www.altoneuroscience.com
-
How do I contact ANRO?
-
ANRO could be contacted at phone #(650) 200-0412 and can also be accessed through its website. ANRO operates from 369 South San Antonio Road, Mountain View, CA 94022, US.
-
How many shares of ANRO are traded daily?
-
The average number of ANRO shares traded daily for last 3 months was 461.2K.
-
What is the market cap of ANRO currently?
-
The market value of ANRO currently stands at $975.61M with its latest stock price at $27.8